Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

(2012) John D Isaacs et al.   ANNALS OF THE RHEUMATIC DISEASES

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

A Systems Approach to Rheumatoid Arthritis

(2012) Sungyong You et al.   PLoS One

Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium

(2011) I. Gutierrez-Roelens et al.   ARTHRITIS AND RHEUMATISM

The anti-CD20 antibody rituximab reduces the Th17 cell response

(2011) Frank L. van de Veerdonk et al.   ARTHRITIS AND RHEUMATISM

How to perform and analyse synovial biopsies

(2009) Daniëlle M. Gerlag et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis

(2009) Valérie Badot et al.   ARTHRITIS RESEARCH & THERAPY

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET